| abstract |
The present invention is based, in part, on the novel, inventive combination of an inhibitor of a mammalian Target of Rapamycin (mTOR) and an inhibitor of a Platelet-Derived Growth Factor Receptor (PDGF-R) in treating or preventing neointimal hyperplasia. The effect is synergistic and long lasting. In some embodiments, the mTOR inhibitor comprises rapamycin and the PDGF-R inhibitor comprises imatinib mesylate. As discussed in greater detail herein, the inhibitors may administered in a common mixture or as a separate composition, they may also be administered in any number of different ways including orally, e.g., by pill, or locally, e.g., by means of a stent coating. |